Overview of Entecavir

Property	Description
Active ingredient	Entecavir (as monohydrate)
Form	Oral tablet, Oral solution
Pharmacological class	Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Common use	Viral suppression in chronic Hepatitis B
Origin	Synthetic analogue (Guanosine)

What Type of Medicine is Entecavir?

Entecavir is an antiviral medication classified as a Nucleoside Reverse Transcriptase Inhibitor (NRTI). This places it within the major pharmaceutical class of agents designed to interrupt the replication cycle of viruses.

The drug is a synthetic analogue, specifically a guanosine nucleoside analogue, manufactured to mimic a natural DNA building block. This design allows for selective activity against the target viral enzyme. Its pharmacological profile is notable for a high genetic barrier to resistance, a feature associated with a sustained treatment response compared to some earlier NRTIs. As a prescription-only drug, its usage is confined to medical direction.

Composition and Available Forms

The medicinal entity is based on the single active ingredient, Entecavir, typically supplied as the monohydrate. This concentration on a singular agent differentiates its composition from combination antiviral therapies.

For patient administration, Entecavir is provided in two oral dosage forms for administration via the oral route: these include solid oral tablets and a liquid oral solution. The availability of an oral solution is a key feature, enabling treatment for patient groups, such as pediatric patients, who may not tolerate solid forms.

General Purpose of the Antiviral Agent

The main purpose of Entecavir is to achieve viral suppression. It works as a Viral Replication Blocker by interfering with the virus’s ability to copy its own genetic material. Entecavir is utilized as a first-line agent for the clinical management of HBV infection, acting to reduce the active multiplication of the virus within the body. By inhibiting the HBV DNA polymerase enzyme, Entecavir reduces the number of circulating viruses, which helps slow the progression of chronic infection and mitigate ongoing damage to the liver.

Regulatory References

Entecavir on WHO Essential Medicines List (eEML)

What side effects are possible with Entecavir?

Possible Side Effects and Safety Information

The safety profile of Entecavir is established by regulatory bodies through classification of observed adverse reactions by frequency and System-Organ Class (SOC). These classifications are based on data from clinical trials and post-marketing surveillance.

Frequency Tier	Documented Side Effects (Examples)	Associated System/Class
Common (1% to 10%)	Headache, Fatigue, Nausea, Dizziness	Nervous System, General Disorders, Gastrointestinal Disorders
Uncommon (0.1% to 1%)	Rash, Alopecia, Urticaria	Skin and Subcutaneous Tissue Disorders
Rare (<0.1%)	Lactic Acidosis, Severe Hepatomegaly	Metabolism, Hepato-biliary Disorders

Serious adverse reactions are explicitly highlighted in official labeling. The most critical safety considerations include the risk of Lactic Acidosis and Severe Hepatomegaly with Steatosis, a rare metabolic disorder associated with nucleoside analogues, and the potential for Severe Acute Exacerbations of Hepatitis B following the discontinuation of treatment. Hepatic function monitoring is required for several months after stopping therapy.

Population-specific safety statements define considerations for certain groups. In patients with renal impairment, drug clearance is reduced, which necessitates careful safety monitoring. For individuals co-infected with HIV and HBV, using Entecavir alone is generally not recommended due to the potential for developing resistance to other anti-HIV Nucleoside Reverse Transcriptase Inhibitors. Time-related safety patterns note that post-treatment exacerbations of Hepatitis B may occur several months after cessation.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Entecavir overdose indicates that documented clinical experience is limited. Officially documented studies involving short-term administration of high doses (up to 20 mg per day for 14 days) did not associate this exposure with any specific adverse events.

Official Overdose Statements

Overdose Context	Regulatory Documentation Summary
Documented Presentations	Limited clinical data; no specific adverse events noted in short-term high-dose exposures.
Serious Outcomes Warning	As part of the nucleoside analogue class, the drug carries a regulatory warning regarding the risk of lactic acidosis and severe hepatomegaly with steatosis (liver enlargement with fat build-up), which includes fatal cases.
Antidote Information	No specific antidote is known for Entecavir overdose.
Management Strategy	Management requires the provision of symptomatic and supportive treatment with mandatory hospital monitoring for potential signs of toxicity.
Drug Removal	Clearance is dependent on renal function. Approximately 13% of the drug is removed by hemodialysis over a four-hour period; negligible amounts are removed by peritoneal dialysis.

When Immediate Medical Help is Required

Following a suspected overdose, it is mandated to seek immediate medical attention or call a healthcare provider right away. Emergency services must be contacted immediately if the individual has collapsed, experienced a seizure, or has trouble breathing.

Therapeutic Uses of Entecavir

What Entecavir Treats: Main Uses and Benefits

Entecavir is commonly used for the long-term management and virologic control of Chronic Hepatitis B virus (HBV) infection. It is relevant in clinical situations where there is evidence of active viral replication and signs of active disease. Its use is applicable across therapeutic contexts, including adults and pediatric patients (aged two years and older). The core therapeutic benefit contributes to supporting stability in the condition and may help ease the long-term risk of severe liver complications. This contributes to supporting long-term liver health during symptomatic phases.

The medication supports the management of the viral load and the associated elevated serum aminotransferase levels (ALT and AST). Addressing these markers contributes to easing the symptom burden of inflammation. Entecavir is used in contexts of chronic active HBV infection, including cases where patients may be dealing with HBV-related compensated or decompensated cirrhosis.

Quick Fact: Relief for Biochemical Markers

Entecavir helps manage internal markers of inflammation, which assists in easing the overall symptom load associated with conditions marked by increased physiological stress.

Eligibility and Restrictions for Use

Who Can and Cannot Use Entecavir?

Entecavir's eligibility profile is strictly defined by regulatory authorities based on patient population, age, comorbidities, and organ function.

Eligibility Status	Defined Population
Contraindicated	Individuals with known hypersensitivity to entecavir or any component of the product.
Not Recommended	Patients co-infected with HIV who are not simultaneously receiving Highly Active Antiretroviral Therapy (HAART).
Conditional Use	Patients with renal impairment (creatinine clearance < 50 mL/min) require a regimen adjustment.
Approved Use	Adults and pediatric patients ge 2 years of age are approved for chronic HBV treatment, including those with compensated or decompensated liver disease.
Use Not Established	Children younger than two years of age (or weighing less than 10 kg).

Eligibility is defined by specific criteria: Use is restricted during lactation (breastfeeding) and during pregnancy is considered only when the potential benefit justifies the risk. The regulatory label specifies no dosage adjustment is necessary for patients with any degree of hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents characterize Entecavir's interaction profile based primarily on its route of elimination and specific co-administration constraints. Entecavir is principally cleared by the kidneys through glomerular filtration and active tubular secretion.

Potential Pharmacokinetic Interactions

Interaction Type	Agents/Categories	Regulatory Statement
Renal Elimination	Drugs that reduce renal function or compete for active tubular secretion	Co-administration may increase the serum concentration of either Entecavir or the co-administered drug.
Specific Antivirals	Lamivudine, Adefovir, Tenofovir	Co-administration studies did not show clinically significant pharmacokinetic interactions.

Interaction-Related Constraints

Food Effect: Administration with a meal, including a high-fat or light meal, decreases the systemic exposure (AUC) and peak concentration (Cmax) of Entecavir. For optimal exposure, particularly in lamivudine-refractory patients, the drug should be taken on an empty stomach (at least two hours before and two hours after a meal).
Co-infection Restriction: The use of Entecavir is officially not recommended for patients co-infected with HIV and HBV who are not simultaneously receiving Highly Active Antiretroviral Therapy (HAART). This restriction is based on the potential for selecting resistance to future HIV nucleoside reverse transcriptase inhibitors.

Mechanism of Action

Intracellular Activation and Target Recognition

The action of Entecavir requires that the molecule be present within the infected hepatocyte. Inside the cell, the molecule is chemically activated through phosphorylation by host enzymes, converting it into its active form: entecavir triphosphate (ETV-TP). This conversion creates a structural mimic of the natural DNA building block, deoxyguanosine triphosphate (dGTP), enabling ETV-TP to interact with the HBV DNA Polymerase, the enzyme that mediates viral replication.

Dual Mechanism of Replication Blockade

The active metabolite, ETV-TP, exerts its effect through a dual-action mechanism against the viral enzyme. First, it engages in competitive inhibition, binding strongly to the polymerase and blocking its ability to process natural substrates. Second, upon ETV-TP incorporation into the forming viral DNA strand, it causes chain termination, immediately halting the synthesis and elongation of the viral genome. This mechanical stop inhibits the ability of the Hepatitis B virus to complete the synthesis of its genetic material.

Consequence: Reduction of Viral DNA

By blocking all three functions of the HBV DNA Polymerase, the mechanism directly and profoundly interrupts the viral life cycle at the point of reproduction. This sharply reduces the production of new infectious particles, leading to a decrease in the level of detectable viral DNA circulating in the blood. This effect reflects the mechanistic constraint of the drug and does not alter the stable viral reservoir (cccDNA) that persists in the hepatocyte nucleus.

Dosage and Administration Information

The administration of Entecavir is structured around a once-daily oral schedule, with the precise regimen depending on the patient's prior treatment history and current liver status. The medicine is supplied as 0.5 mg and 1 mg film-coated tablets, and as an oral solution (0.05 mg/mL) used for reduced-dose regimens and weight-based pediatric dosing.

Dosage and Administration Protocol

Patient Group	Recommended Once-Daily Dose	Meal Requirement
Nucleoside-Naïve (Compensated)	0.5 mg	May be taken with or without food.
Lamivudine-Refractory or Decompensated	1 mg	Must be taken on an empty stomach (at least 2 hours before and 2 hours after a meal).

The 1 mg dose requires strict adherence to the empty stomach condition. The oral solution must be accurately measured using the dedicated dispensing tool and should not be diluted or mixed with other liquids.

Special Procedural Constraints

Renal Function: A dose adjustment is required for patients with impaired kidney function (creatinine clearance less than 50 mL/min). This involves altering the dosing interval (e.g., every 48 or 72 hours) or reducing the daily dose. For patients undergoing haemodialysis, the dose must be administered after the dialysis session is complete.

Missed Dose: If a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose must be skipped. A double dose must not be taken to compensate.

Cessation: The discontinuation of Entecavir is generally not recommended for patients with advanced liver disease, such as decompensated liver disease or cirrhosis.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Entecavir

Evidence for Use in Patients Not Previously Treated with Nucleoside Analogues

The primary research for entecavir in patients who had not received prior nucleoside-based therapy consists of large, randomized, controlled Phase 3 trials. These trials included adults and adolescents, and groups with pre-existing compensated liver damage. Findings from the initial 48-week period described patterns of viral suppression across the study groups. Trials comparing entecavir to an older nucleoside therapy reported differing rates of virologic response and resistance emergence between the two groups.

What remains less established is the full potential for HBsAg seroclearance—an endpoint tracked in research—which is difficult to achieve; research indicates this is an infrequent endpoint. Additionally, for some patients, the duration of therapy needed to achieve predefined virologic endpoints is a complex question that remains the subject of ongoing investigation.

Research on Patients with Prior Lamivudine Treatment

The clinical trial landscape for individuals who have already received and were classified as lamivudine-experienced included randomized Phase 3 trials that specifically studied entecavir in adults who had documented signs of viral resistance to lamivudine. These studies closely monitored virologic suppression as well as the emergence of genotypic drug resistance.

Trials reported that patients who switched to entecavir had observable changes in viral levels. However, the studies noted a greater probability of the virus developing resistance in this group compared to patients who had never been treated with nucleoside analogues before.

Evidence in Patients with Advanced Liver Disease (Decompensated Cirrhosis)

The evidence for this indication relies heavily on prospective and retrospective cohort studies and meta-analyses. Researchers monitored important clinical outcomes, including survival, virologic suppression, and changes in liver function scores. Cohort studies reported patterns of HBV DNA suppression and observable changes in liver function markers in the observed patients. Comparative observational data described similar rates of survival in the two groups (entecavir and lamivudine) in this high-risk population.

What Remains Uncertain in the Research Landscape

While the research landscape is extensive, certain areas remain complex or insufficiently studied. HBsAg seroclearance is consistently described as an endpoint that is difficult to achieve. For some patient groups, such as lamivudine-refractory patients, the risk of resistance remains a key limitation noted in the research.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Entecavir (FAQ)

Q: Does Entecavir need to be taken at the exact same time every day?

Official information advises that taking this medicine at approximately the same time each day can help with consistent adherence. This approach is described in the official guidance as supporting consistent adherence to the regimen.

Q: Can Entecavir affect the results of blood tests?

Regulatory documents state that liver function must be monitored closely with blood tests during treatment and for several months after stopping the medicine. This monitoring is conducted to monitor for changes in liver health, including the potential for a severe exacerbation of Hepatitis B.

Q: Is there a generic version of Entecavir available?

Yes, this medicine is available under the brand name (such as Baraclude) and also as generic versions of the tablets and oral solution. This availability is confirmed across multiple government drug registers.

Q: What studies have been done on the use of Entecavir in the elderly?

Clinical studies on the use of Entecavir included subjects who were 65 years of age and older. According to the official prescribing information, specific dose adjustments based only on a person's age are generally not required.

Q: What information is available about Entecavir for people who are nursing?

Official guidance advises that breastfeeding is not recommended while taking Entecavir. Official prescribing information cites this restriction because it is not known whether the medicine is excreted into human breast milk.

Q: Does Entecavir cause dizziness or affect driving ability?

Adverse reactions such as dizziness and fatigue have been commonly reported in clinical trials. Official documents advise that if a person experiences dizziness or sleepiness, their ability to drive or operate machinery may be impacted.

Q: Do specific research studies show Entecavir is effective in preventing liver damage?

Clinical studies described in official documents demonstrate that the treatment led to histological improvement in liver tissue. This improvement is associated with mitigating ongoing liver damage.

Q: How long does it typically take to see any effect from Entecavir?

The optimal duration of treatment is not known and varies by person. The time it takes to reach specific viral endpoints, such as HBeAg seroconversion, is generally measured in months or even years of consistent therapy.

Q: Does Entecavir interact with common pain relievers like Tylenol (acetaminophen)?

Official documents describe a potential for interaction with medicines that reduce kidney function or compete for active tubular secretion. Official regulatory documents do not cite specific clinical interaction studies with common pain relievers such as acetaminophen.

Q: Is Entecavir safe for use during pregnancy?

The official guidance states that the medicine should only be used during pregnancy if the potential benefit justifies the potential risk to the developing fetus. A Pregnancy Registry exists to collect information on maternal-fetal outcomes associated with its use.

Q: What is the risk of the hepatitis B coming back after stopping Entecavir?

The official label includes a warning about the risk of severe acute exacerbations of Hepatitis B following the discontinuation of anti-Hepatitis B therapy. This risk requires careful post-treatment monitoring of liver function.

Q: Is Entecavir used for long-term or short-term treatment?

The optimal duration of treatment with Entecavir is not currently known, and therapy is often administered for prolonged periods. The decision to stop treatment is based on specific virologic and serologic criteria assessed by a healthcare professional.

Q: Why is regular monitoring (like blood work) necessary while on Entecavir?

Regular monitoring of liver function is necessary for reasons described in official documents. First, monitoring is conducted due to the risk of severe acute exacerbations of Hepatitis B. Second, it allows for the early detection of signs of rare but serious adverse reactions, such as lactic acidosis or pronounced hepatotoxicity.

Q: Does Entecavir interact with blood pressure medication?

Official documents advise caution with co-administration of drugs that reduce kidney function or compete for active tubular secretion. Official documents state that co-administration may increase the serum concentration of either Entecavir or the co-administered drug.

Q: Does Entecavir have a black box warning?

Yes, the US FDA label includes a Boxed Warning, which is a high-level caution. The warning highlights the risks of severe acute exacerbations of hepatitis B after discontinuation, the risk for patients co-infected with HIV/HBV, and the risk of lactic acidosis and hepatomegaly with steatosis.

Q: Is a person on Entecavir still contagious?

Entecavir is an antiviral medicine that works by suppressing the virus in the body, but it does not eliminate it entirely. Official sources caution that the transmission of the virus may still be possible.

Q: What are the long-term effects of taking Entecavir for many years?

The optimal duration of therapy is not yet known. The relationship between prolonged Entecavir treatment and long-term outcomes, such as the development of cirrhosis or liver cancer (hepatocellular carcinoma), is still under investigation.

Q: Are there specific symptoms that require immediate medical attention while taking Entecavir?

The official label highlights symptoms that could suggest a rare but serious adverse reaction called lactic acidosis. These symptoms include unusual muscle pain, weakness, or trouble breathing, and are highlighted in the regulatory materials as requiring immediate evaluation.

Q: Are there reports of sleep problems associated with Entecavir?

Some official consumer-facing information lists trouble sleeping (insomnia) or sleepiness (somnolence) as reported side effects. These are typically described as less common events observed during clinical use.

Q: What are the general expectations for a person's liver function while on Entecavir?

Clinical studies indicate that viral suppression is associated with improvements in serum aminotransferase levels, which are blood markers used to measure liver health.

Q: Is a prescription required for Entecavir?

Yes, Entecavir is classified as a prescription-only medicine (POM). It requires authorization from a healthcare professional and cannot be purchased over the counter.

Q: Are there any limitations on physical activity while using Entecavir?

While general limitations on physical activity are not widely cited, official information advises caution, particularly during aerobic exercise, due to the rare but serious risk of lactic acidosis, a metabolic disorder associated with nucleoside analogues.

Q: Can Entecavir be taken by people with heart conditions?

According to the official prescribing information on contraindications, having a heart condition is not specifically listed as a reason to avoid taking Entecavir.

How should Entecavir be stored and disposed of?

How to Store and Dispose of Entecavir

Entecavir tablets and oral solution must be stored at a controlled room temperature, specifically between 68 F and 77 F (20 C to 25 C). It is mandatory to keep the medicine in its original container with the lid tightly closed and protect it from light, moisture, and freezing.

To ensure child safety, Entecavir must be stored out of the sight and reach of children.

Disposal Requirements

Unused or expired product must be disposed of according to official regulatory guidelines, such as those provided by the FDA or a healthcare professional. The medicine should not be thrown away in household waste or wastewater, adhering to pharmaceutical waste regulations to protect the environment.

Entecavir